Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Xilio Therapeutics, Inc. - Common Stock (NQ:XLO)

0.8018 +0.0018 (+0.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,044
Open 0.8018
Bid (Size) 0.8102 (100)
Ask (Size) 0.8307 (500)
Prev. Close 0.8000
Today's Range 0.8018 - 0.8018
52wk Range 0.6150 - 1.700
Shares Outstanding 51,827,910
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics to Present Phase 2 Data for Vilastobart Highlighting Response Rate in Patients with MSS mCRC and High Plasma Tumor Mutational Burden as a Late-Breaking Presentation at SITC 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-25.1%
-25.1%
1 Month
-2.8%
-2.8%
3 Month
+20.3%
+20.3%
6 Month
+15.7%
+15.7%
1 Year
-44.3%
-44.3%

More News

Read More
Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer (SITC) 40th Annual Meeting
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Stock Jumps 8% On Cancer Drug Data; Gilead Boost Extends Cash Runway Into 2027 — Retail Says Stock Undervalued
Via Stocktwits
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Initiation of Phase 2 Trial for Efarindodekin Alfa (XTX301), a Tumor-Activated IL-12, and Achievement of $17.5 Million Development Milestone Under Exclusive License Agreement with Gilead
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Revenue Jumps 246 Percent in Q2
Via The Motley Fool
Topics Intellectual Property
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2025 Financial Results
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Appoints Daniel Curran, MD, to its Board of Directors
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Xilio Therapeutics Appoints Akintunde Bello, Ph.D., to its Board of Directors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Closing of $50.0 Million Public Offering
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Here are the top movers in Monday's session.
Via Chartmill
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Nasdaq Edges Higher; ISM Manufacturing PMI Falls In May
Via Benzinga
Which stocks are experiencing notable movement on Monday?
Via Chartmill
Which stocks are gapping on Monday?
Via Chartmill
Dow Dips Over 300 Points; Campbell's Posts Upbeat Earnings
Via Benzinga
Topics Stocks
Xilio Therapeutics Announces Pricing of $50.0 Million Public Offering
From Xilio Therapeutics, Inc.
Via GlobeNewswire
These stocks that are showing activity before the opening bell on Monday.
Via Chartmill
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Blueprint Medicines Shares Are Trading Higher By 27%; Here Are 20 Stocks Moving Premarket
Via Benzinga

Frequently Asked Questions

Is Xilio Therapeutics, Inc. - Common Stock publicly traded?
Yes, Xilio Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Xilio Therapeutics, Inc. - Common Stock trade on?
Xilio Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Xilio Therapeutics, Inc. - Common Stock?
The ticker symbol for Xilio Therapeutics, Inc. - Common Stock is XLO on the Nasdaq Stock Market
What is the current price of Xilio Therapeutics, Inc. - Common Stock?
The current price of Xilio Therapeutics, Inc. - Common Stock is 0.8018
When was Xilio Therapeutics, Inc. - Common Stock last traded?
The last trade of Xilio Therapeutics, Inc. - Common Stock was at 11/04/25 04:00 PM ET
What is the market capitalization of Xilio Therapeutics, Inc. - Common Stock?
The market capitalization of Xilio Therapeutics, Inc. - Common Stock is 41.56M
How many shares of Xilio Therapeutics, Inc. - Common Stock are outstanding?
Xilio Therapeutics, Inc. - Common Stock has 42M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.